Radiopharmaceuticals
Discovery and development of radioligands, targeting vectors, chelators and new radiochemistry.
Research insight platform
Following the frontier of nuclear medicine.
追踪全球与中国核医学前沿
China NucMed follows the latest advances in research, development and clinical application of nuclear medicine — from radiopharmaceutical discovery to molecular imaging and isotope supply — across the world and in China.
What we follow
Six areas shaping the field
We track the science, the pipeline and the policy that move nuclear medicine from the laboratory to the clinic.
Theranostics
Paired diagnostic and therapeutic agents — "see what you treat" — and the evidence behind targeted radionuclide therapy.
Molecular imaging
PET, SPECT and hybrid systems, total-body scanners, novel tracers and AI-assisted image analysis.
Isotope supply
Reactors, cyclotrons and generators; production capacity, supply chains and the race for scarce isotopes.
Clinical trials & approvals
Trial readouts, regulatory milestones and real-world adoption across major markets.
Industry & policy
Deals, financing, manufacturing build-outs, reimbursement and the policy frameworks that shape access.
Isotopes in focus
The radionuclides behind the headlines
From workhorse imaging agents to the alpha emitters driving the next wave of targeted therapy.
Dx99mTc
SPECT workhorse, generator-produced from Mo-99
Dx18F
Cyclotron-produced PET tracers such as FDG
Dx68Ga
Generator-based PET for PSMA and SSTR imaging
Tx177Lu
Beta emitter for radioligand therapy
Tx225Ac
Alpha emitter for next-generation therapy
Tx131I
Long-established thyroid therapy
Two lenses
A global view, with depth on China
China is one of the fastest-developing nuclear medicine markets in the world. We connect what happens there to the global picture — and back.
Global
Worldwide advances
- Pivotal trials and approvals in radioligand therapy
- New targets, vectors and alpha-emitter programs
- Isotope production capacity and supply-chain resilience
- Guidelines and practice updates from leading societies
China · 中国
Developments in China
- Domestic medical isotope production and long-term planning
- NMPA registrations and innovative radiopharmaceutical pipelines
- PET/SPECT installation growth and hospital department build-out
- Academic output, partnerships and cross-border licensing
Our approach
Signal over noise
Nuclear medicine moves across chemistry, physics, oncology, regulation and industry at once. We follow the primary sources and turn them into clear, structured insight.
Monitor
Peer-reviewed literature, conference proceedings, trial registries, regulatory databases and company disclosures.
Curate
Filter for what is genuinely new and clinically or commercially significant.
Analyse
Put each development in context — scientific, regulatory and market — globally and in China.
Share
Concise briefings and research insights for clinicians, researchers, industry and investors.